Search

everythinglearnresearchcommunity

for

Search:↓

Febron Hair fiber quality has decreased since post-pandemic era, causing fibers to stick to fingers. Users seek better brand recommendations.

Nizoral is a suitable replacement for Ketoconazole, but ensure it contains 2% Ketoconazole. The yellow bottle is recommended and should last 3-4 months if used twice a week.

The user's progress with hair loss treatments of 0.5mg finasteride daily, minoxidil 5%, and nizoral 2%. They discuss if further growth is possible, their experience after two months, and encourage others to not lose hope.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

A humorous discussion about a newborn's hair loss, jokingly suggesting treatments like Minoxidil, finasteride, and various other hair loss remedies. Participants humorously debate extreme measures, including shaving or using a "nuclear stack" of treatments.

A 113 year old man who has more hair than most people, and the conversation is discussing potential genetic factors that may be responsible for this. Possible treatments such as dermarolling and minoxidil, finasteride, and RU58841 are mentioned.

People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

A 22-year-old male is experiencing hair loss due to seborrheic dermatitis, not male pattern baldness, and is seeking advice. Suggestions include using Nizoral, sulfate-free and ketoconazole shampoos, cutting hair short, using cold water, avoiding picking scabs, and trying selenium sulfide shampoo or finasteride.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

User uses 1ml RU58841 with 5ml stemoxydine for scalp coverage. Wants to switch to pyrilutamide and asks about mixing it with other compounds.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.

The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.

A user shared their 11-month experience using a 272 diode red light hat for hair loss, noting decent results despite inconsistent use and no medication. Another user suggested that real treatment like minoxidil or finasteride is necessary for long-term hair maintenance.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.

User shows hair loss progress from NW4 to NW2.5 in 2.5 months using RU 8.5-9% daily and topical Dut .1% + RU 5% weekly. Discussion includes managing tension in African American hair and representation of different hair types.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

OP bought Koshine x826 and plans to update on its effectiveness, currently using fluridil. OP couldn't tolerate RU or DUT, while another user mixes Dutasteride with Koshine x826 weekly without side effects.

User tried finasteride, minoxidil, and nizoral for hair loss with minor results. Derma rolling improved hair thickening significantly.

The user asks about the order and compatibility of using topical minoxidil, stemoxydine, The Ordinary natural moisturizing factors + HA for scalp, RU58841, and Nioxin system 2 leave-in treatment. They seek advice on layering these hair loss treatments.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conversation discusses using Nizoral 2% for hair loss treatment without having dandruff, with advice on allowing it to absorb for 10 minutes before rinsing and a personal experience of the product causing dry and itchy scalp.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.